Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma()

INTRODUCTION: Daratumumab is a CD38-targeting monoclonal antibody with established efficacy and safety in patients with relapsed or refractory multiple myeloma (RRMM). We report results of an early access protocol (EAP) of daratumumab monotherapy for RRMM in a cohort of Brazilian patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Crusoé, Edvan de Queiroz, Pimenta, Flávia Cristina Fernandes, Maiolino, Angelo, Castro, Nelson Siqueira de, Pei, Huiling, Trufelli, Damila, Fernandez, Mariana, Herriot, Luciana Barreto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573022/
https://www.ncbi.nlm.nih.gov/pubmed/32967807
http://dx.doi.org/10.1016/j.htct.2020.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573022/
https://www.ncbi.nlm.nih.gov/pubmed/32967807
http://dx.doi.org/10.1016/j.htct.2020.07.005

Ejemplares similares